X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition is a key part of the Group’s international growth strategy and will enable Biocodex to consolidate its presence in the digestive health and women’s health segments of the US market.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Hilma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 17, 2022
Details:
DIACOMIT (stiripentol) is an effective treatment for seizures that are often resistant to other antiepileptic drugs. In two clinical studies, DIACOMIT reduced generalized clonic or tonic-clonic seizures by a median of 84% compared with 5.8% on placebo after two months.
Lead Product(s): Stiripentol
Therapeutic Area: Neurology Product Name: Diacomit
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
DIACOMIT (stiripentol), is a molecular entity approved by the FDA for the adjunctive treatment of seizures associated with Dravet syndrome in 2 years of age and older taking clobazam. An orally administered, DIACOMIT is given as either a capsule or powder for suspension.
Lead Product(s): Stiripentol
Therapeutic Area: Neurology Product Name: Diacomit
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: PANTHERx Rare Pharmacy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
